March 9, 2007 -- A new analysis that compared 3 common treatment options for prostate cancer found a difference between them. Men who were treated with external-beam radiotherapy did not live as long ...

But does it cost too much?

Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

SEOUL, South Korea, March 19, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in ...

Halda has advanced the next wave of induced proximity drugs into the clinic, expanding the case for bifunctional molecules that act by sticking two proteins together. Whereas the first act for these ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

The MarketWatch News Department was not involved in the creation of this content. Repertoire and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research ...